# Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

> **NCT00611858** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 13 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** 5-Fluorouracil
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT00611858
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2012-12
- **Final completion:** 2016-09
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2019-01-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00611858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00611858, "Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00611858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*